{"filing":{"accession_number":"0001193125-26-261696","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"dyn-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/dyn-20260605.htm"},"events":[{"id":6195,"run_id":5440,"accession_number":"0001193125-26-261696","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of Dyne Therapeutics' 2026 Annual Meeting of Stockholders held on June 5, 2026, including votes on director elections (David Lubner, Brian Posner, Jason Rhodes), advisory compensation approval, authorization of additional common shares (200M to 400M), officer exculpation amendment, and auditor ratification. The filing presents tabulated voting results for each matter, which is the core disclosure required under Item 5.07 for shareholder vote results.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5169,"accession_number":"0001193125-26-261696","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Dyne Therapeutics' 2026 Annual Meeting of Stockholders held on June 5, 2026, including votes on director elections (David Lubner, Brian Posner, Jason Rhodes), advisory compensation approval, authorization of additional common shares (200M to 400M), officer exculpation amendment, and auditor ratification. The filing presents tabulated voting results for each matter, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:35.051991+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5169,"accession_number":"0001193125-26-261696","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Dyne Therapeutics' 2026 Annual Meeting of Stockholders held on June 5, 2026, including votes on director elections (David Lubner, Brian Posner, Jason Rhodes), advisory compensation approval, authorization of additional common shares (200M to 400M), officer exculpation amendment, and auditor ratification. The filing presents tabulated voting results for each matter, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:35.051991+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-08"}]}